ARRY520 monotherapy result in rrMM was reported last year at ASH. It was very disappointing. I don't think there is path forward as monotherapy. It is supposed to work well in combination with proteasome inhibitors based on preclinical data. No clinical data yet.
Market Data 
Markets 
AI
